Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...

Delve into the STAT6 degrader technology and what it could bring to inflammatory and allergic disease treatment.

The budget cuts threaten global progress on everything from heart disease to H.I.V. — and could affect American drug ...

This month, lenacapavir is expected to receive FDA approval for pre-exposure prophylaxis (PrEP). It could very well be that ...

Gilead Sciences Inc. closed 9.97% short of its 52-week high of $119.96, which the company reached on March 10th.

Lenacapavir, a twice-yearly HIV prevention shot by Gilead, could be produced for $25 a year but may sell for $25K, raising ...

Analysts at Truist Securities called J&J’s CAR-T readout “compelling,” noting that the efficacy figures could position the ...

Gilead Sciences shows strong Q1 execution, pipeline momentum, and margin upside, led by HIV and PrEP launches. See why GILD ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Goldman Sachs analyst ...

The firm’s analysis suggests that high clinician engagement, lower-than-expected adherence to oral PrEP medications, and the ...

Gilead’s HIV treatment trials involving an investigational integrase strand inhibitor (GS-1720) and an investigational capsid inhibitor (GS-4182) have been put on clinical hold by the Food and Drug ...

During the first quarter, the Global Women’s Leadership portfolio lagged global developed market equities overall in the ...